- Home
- PETS vs ACET Comparison
PETS vs ACET Comparison
Compare PETS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | ACET |
|---|---|---|
| Founded | 1996 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 69.6M |
| IPO Year | 2003 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PETS | ACET |
|---|---|---|
| Price | $2.37 | $7.24 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.20 | ★ $65.33 |
| AVG Volume (30 Days) | 105.8K | ★ 130.1K |
| Earning Date | 01-01-0001 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $273,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $0.45 |
| 52 Week High | $4.32 | $9.05 |
Technical Indicators
Market Signals| Indicator | PETS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 25.37 | 50.32 |
| Support Level | N/A | $6.54 |
| Resistance Level | $2.93 | $8.46 |
| Average True Range (ATR) | 0.11 | 0.48 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 14.04 | 37.93 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.